New application

Article

The first femtosecond-only method of laser vision correction from Carl Zeiss Meditec is now available for sale outside the United States.

The first femtosecond-only method of laser vision correction from Carl Zeiss Meditec is now available for sale outside the United States. ReLEx is a new application that allows ophthalmic surgeons to perform a variety of complete laser vision correction procedures using only the VisuMax Femtosecond laser.

ReLEx allows for very small flap sizes, typically just 0.5 to 1 mm larger in diameter than the optical zone. Furthermore, ReLEx provides an easier and much faster workflow for the surgeon as the entire procedure can be performed using a single laser. To date, ReLEx procedures have been performed on more than 1000 eyes at a variety of locations outside the US.

In a recent study in which the ReLEx Femtosecond Lamellar Extraction (FLEX) method was performed by Professor Osama Ibrahim, MD at ALEX Laser Center in Alexandria, Egypt, ReLEx compared favourably to LASIK in terms of efficacy, stability, and safety. 102 eyes (71 female eyes and 31 male eyes) with myopia or myopic astigmatism with a spherical equivalent of -5.07 D ± 2.77 D were treated. At the 3-month follow-up, 95% of eyes treated were within ± 1.00 D and 76% of eyes were within ± 0.50 D of intended correction. Mean spherical equivalent was -0.17 D ± 0.64 D at 1 month. Stability was seen at one week postoperatively. A total of 85% of eyes achieved an uncorrected distance visual acuity (UDVA) of 20/20 or greater at 1 month and 84% of eyes showed UDVA of 20/25 or better at day one.

No change in corrected distance visual acuity (CDVA) was reported in 69% of eyes however, a gain of one or more lines was achieved in 9% of eyes. A loss of more than 2 lines occurred in 2 percent at 1 month.

“Until now, laser vision correction has been a two-part process in which the patient must be moved from one platform to another, ” said Professor Osama Ibrahim. “With ReLEx using the VisuMax Femtosecond Laser, I achieved consistently excellent visual outcomes while enhancing patient comfort, both of which are essential to achieve a high level of satisfaction in today’s elective surgery environment. ”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.